Jeevan Scientific Technology (BSE 538837)₹80.81−0.07%Healthcare Research, Analytics & Technology
In the Jun 2026 quarter (consolidated), Jeevan Scientific Technology reported sales of ₹18.36 Cr, up 107.7% from Jun 2025, and net profit of ₹0.88 Cr. For the year to Mar 2026, sales were ₹61.82 Cr and net profit ₹1.04 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8.10 | 10.17 | 11.12 | 12.92 | 11.45 | 12.55 | 10.09 | 8.84 | 12.43 | 19.13 | 21.39 | 18.36 |
| Expenses | 7.44 | 9.09 | 10.06 | 9.61 | 8.87 | 10.40 | 10.40 | 10.54 | 10.28 | 13.80 | 16.95 | 15.28 |
| Operating Profit | 0.61 | 1.02 | 0.99 | 3.24 | 2.51 | 2.08 | −0.39 | −1.79 | 2.08 | 5.25 | 4.30 | 2.96 |
| OPM % | 7.4% | 9.9% | 8.8% | 25.0% | 21.9% | 16.5% | −3.8% | −20.3% | 16.7% | 27.4% | 20.1% | 16.1% |
| Other Income | 0.27 | −0.12 | 0.24 | 0.12 | 0.17 | 0.24 | 0.16 | 0.34 | 0.21 | 0.15 | 0.30 | 0.18 |
| Interest | 0.25 | 0.14 | 0.32 | 0.32 | 0.44 | 0.42 | 0.54 | 0.53 | 0.54 | 0.53 | 0.40 | 0.43 |
| Depreciation | 1.42 | 1.39 | 1.63 | 1.50 | 1.48 | 1.47 | 1.76 | 1.73 | 1.68 | 1.59 | 1.60 | 1.69 |
| Profit before tax | −0.84 | −0.66 | −0.77 | 1.49 | 0.73 | 0.40 | −2.56 | −3.74 | 0.04 | 3.24 | 2.57 | 0.97 |
| Tax % | −25.3% | −24.6% | −3.9% | 31.4% | 65.3% | 89.8% | −50.6% | −13.6% | 66.7% | 25.8% | 28.6% | 11.3% |
| Net Profit | −0.62 | −0.50 | −0.74 | 1.04 | 0.26 | 0.06 | −1.27 | −3.23 | 0.02 | 2.41 | 1.85 | 0.88 |
| EPS (Rs) | −0.38 | −0.30 | −0.48 | 0.69 | 0.15 | 0.06 | −0.81 | −1.95 | −0.05 | 0.89 | 0.80 | 0.26 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 17.45 | 18.29 | 20.47 | 26.23 | 24.03 | 47.08 | 68.05 | 36.31 | 39.82 | 46.99 | 61.82 | 71.31 |
| Expenses | 15.54 | 14.96 | 16.91 | 20.21 | 29.91 | 29.29 | 50.85 | 34.68 | 34.91 | 39.20 | 51.59 | 56.31 |
| Operating Profit | 1.81 | 3.21 | 3.44 | 5.88 | −6.10 | 17.54 | 16.82 | 1.37 | 4.66 | 7.50 | 9.83 | 14.59 |
| OPM % | 10.3% | 17.5% | 16.8% | 22.4% | −25.5% | 37.2% | 24.7% | 3.7% | 11.6% | 15.9% | 15.9% | 20.5% |
| Other Income | 0.38 | 0.59 | 0.93 | 1.01 | 2.51 | 2.40 | 5.92 | 1.08 | 0.68 | 0.66 | 0.98 | 0.84 |
| Interest | 1.27 | 1.53 | 1.86 | 2.35 | 3.03 | 2.25 | 0.95 | 1.03 | 0.97 | 1.81 | 2.03 | 1.90 |
| Depreciation | 0.67 | 1.22 | 2.11 | 3.12 | 3.91 | 3.96 | 3.68 | 5.06 | 5.92 | 6.24 | 6.63 | 6.56 |
| Profit before tax | 0.22 | 1.02 | 0.37 | 1.38 | −10.53 | 13.66 | 18.04 | −3.67 | −1.61 | 0.06 | 2.10 | 6.82 |
| Tax % | 104.8% | 10.9% | 69.5% | 18.3% | −18.6% | 14.1% | 33.8% | −16.6% | −17.4% | −20.0% | 50.8% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.01 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | −0.02 | 0.91 | 0.12 | 1.12 | −8.62 | 11.77 | 11.99 | −3.08 | −1.34 | 0.06 | 1.04 | 5.16 |
| EPS (Rs) | −0.01 | 0.96 | 0.09 | 0.72 | −5.60 | 7.66 | 7.79 | −1.96 | −0.85 | 0.07 | 0.57 | 1.90 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 6.5% | 15.4% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | — | 6.05 | 9.29 | 11.48 | 15.33 | 15.32 | 15.33 | 15.35 | 15.51 | 15.52 | 15.84 | 19.97 |
| Reserves | — | −2.26 | 7.59 | 10.54 | 16.51 | 7.90 | 19.69 | 35.30 | 32.72 | 32.95 | 34.08 | 52.03 |
| Borrowings | — | 11.11 | 8.47 | 18.81 | 18.18 | 18.00 | 10.37 | 12.59 | 10.13 | 13.44 | 20.63 | 21.34 |
| Other Liabilities | — | 5.55 | 5.58 | 8.55 | 11.34 | 12.72 | 20.70 | 14.82 | 7.67 | 6.06 | 7.79 | 13.44 |
| Total Liabilities | — | 20.45 | 30.93 | 49.38 | 61.36 | 53.94 | 66.09 | 78.06 | 66.03 | 67.97 | 78.34 | 107 |
| Fixed Assets | — | 8.66 | 16.34 | 28.11 | 32.54 | 30.52 | 27.32 | 19.03 | 24.95 | 26.64 | 34.50 | 36.04 |
| CWIP | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.89 | 2.80 | 4.70 | 4.70 |
| Investments | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.97 |
| Other Assets | — | 11.79 | 14.59 | 21.27 | 28.82 | 23.42 | 38.77 | 59.03 | 39.19 | 38.53 | 39.14 | 63.07 |
| Inventories | 2.28 | 2.29 | 0.48 | 0.11 | 0.24 | 0.96 | 3.47 | 1.47 | 0.88 | 1.10 | 1.63 | 3.04 |
| Trade receivables | 7.32 | 7.22 | 11.29 | 16.26 | 14.65 | 6.82 | 14.42 | 7.59 | 11.65 | 12.27 | 15.90 | 20.63 |
| Cash & equivalents | 0.05 | 0.20 | 0.25 | 1.41 | 3.66 | 2.19 | 6.20 | 29.68 | 6.82 | 0.53 | 0.23 | 9.50 |
| Total Assets | — | 20.45 | 30.93 | 49.38 | 61.36 | 53.94 | 66.09 | 78.06 | 66.03 | 67.97 | 78.34 | 107 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 3.54 | −5.61 | 5.66 | 4.03 | 0.00 | 4.94 | 19.55 | −6.42 | 2.88 | 10.06 | 0.41 |
| Cash from investing activity | −3.62 | −8.87 | −14.30 | −7.85 | −1.89 | −0.79 | −1.19 | −6.91 | −11.50 | −15.58 | −9.95 |
| Cash from financing activity | 0.22 | 14.53 | 9.82 | 6.06 | 0.43 | −0.12 | 5.65 | −9.51 | 2.34 | 5.22 | 18.75 |
| Net cash flow | 0.14 | 0.04 | 1.16 | 2.24 | −1.46 | 4.01 | 23.97 | −22.85 | −6.28 | −0.29 | 9.24 |
| Capex | 3.69 | 8.89 | 14.33 | 7.86 | 1.98 | 0.79 | 2.33 | 8.15 | 12.02 | 16.02 | 8.17 |
| Free cash flow | −0.09 | −14.54 | −8.72 | −3.84 | −1.92 | 4.16 | 17.36 | −14.60 | −9.16 | −5.97 | −7.78 |
| CFO / OP % | 197.0% | −176.0% | 165.0% | 69.0% | 31.9% | 39.0% | 152.9% | −269.1% | 101.0% | 135.0% | 5.0% |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 153 | 228 | 293 | 206 | 105 | 113 | 42 | 119 | 114 | 125 | 124 |
| Inventory days | — | — | — | — | — | — | 72 | 106 | 104 | 156 | 227 |
| Days payable | — | — | — | — | — | — | 99 | 323 | 205 | 305 | 458 |
| Cash conversion cycle | 152 | 227 | 292 | 205 | 104 | 112 | 14 | −99 | 12 | −26 | −109 |
| Working capital days | 52 | 91 | 35 | −3 | −101 | 37 | 10 | 111 | 137 | 128 | 121 |
| ROCE % | — | 12.7% | 6.7% | 8.2% | −16.5% | 36.7% | 27.6% | −4.4% | −1.0% | 2.8% | 5.0% |
For the Jun 2026 quarter, Jeevan Scientific Technology reported sales of ₹18.36 Cr, up 107.7% year on year and net profit of ₹0.88 Cr. The operating margin was 16.1%.
Jeevan Scientific Technology's sales for the year to Mar 2026 were ₹61.82 Cr; over the last twelve months they were ₹71.31 Cr.
Net profit for the year to Mar 2026 was ₹1.04 Cr, and ₹5.16 Cr over the last twelve months. Earnings per share over the same trailing period were ₹1.90.
Jeevan Scientific Technology reported borrowings of ₹21.34 Cr at Mar 2026, against cash and equivalents of ₹9.50 Cr.
Cash from operations was ₹0.41 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹7.78 Cr.